Search

Displaying results 5721 - 5730 of 10000 in total
  1. Drug

    Phosphonotyrosine

    go.drugbank.com/drugs/DB01962
    Experimental

    An amino acid that occurs in endogenous proteins. Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly in cell growth control and carcinogenesis.

  2. Drug

    Sus scrofa placenta

    go.drugbank.com/drugs/DB14243
    Investigational

    Sus scrofa placenta is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.

  3. Drug

    GSK-239512

    go.drugbank.com/drugs/DB15120
    Investigational

    GSK-239512 is under investigation in clinical trial NCT00474513 (An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.).

  4. Drug

    Fosmanogepix

    go.drugbank.com/drugs/DB15183
    Investigational

    Fosmanogepix is under investigation in clinical trial NCT03604705 (An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia).

  5. Drug

    Cyclopenthiazide

    go.drugbank.com/drugs/DB13532
    Approved

    In a double blind, randomized crossover study, cyclopenthiazide was effective in reducing diastolic blood pressure in mildly hypertensive non-insulin dependent diabetic patients [A27180].

  6. Drug

    Quinaprilat

    go.drugbank.com/drugs/DB14217
    Experimental

    The active metabolite of the prodrug quinapril.

    Categories: Agents Acting on the Renin-Angiotensin System
  7. Drug

    Faropenem medoxomil

    go.drugbank.com/drugs/DB05659
    Investigational

    Faropenem medoxomil is an ester prodrug derivative of the beta-lactam antibiotic [faropenem].

  8. Drug

    Norethynodrel

    go.drugbank.com/drugs/DB09371
    Approved

    It has been used in the treatment of functional uterine bleeding and endometriosis. As a contraceptive, it has usually been administered in combination with MESTRANOL.

  9. Drug

    INM005

    go.drugbank.com/drugs/DB16499
    Investigational

    INM005 was under investigation in clinical trials for the treatment of COVID-19. It was studied for pharmacokinetics, efficacy, and safety in a completed trial (NCT04494984).

  10. Drug

    Bezitramide

    go.drugbank.com/drugs/DB01459
    ApprovedIllicitWithdrawn

    After cases of fatal overdose in the Netherlands in 2004 the drug was withdrawn from the market. Bezitramide has never been FDA approved and is currently a schedule II drug. … Bezitramide is a narcotic analgesic which was discovered in 1961, clinically tested around the 1970's [A14383], and marketed under the name Burgodin.